Presented By Shin Fujita at 2016 ASCO Annual Meeting

Slides:



Advertisements
Similar presentations
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Advertisements

Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.
First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.
Presented By Patrick Wen at 2014 ASCO Annual Meeting
Presented By Raymond Huang at 2014 ASCO Annual Meeting
CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.
Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.
A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.
Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.
The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid.
Japanese Approach to colon cancer and the Outcome Dep. of Surgical Oncology Tokyo Medical and Dental University Kenichi Sugihara.
Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.
Title of the Paper Your Name Critical Care Medicine School of Medicine University of Pittsburgh.
Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS , ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.
A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.
Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
J. Lujan, G. Valero, Q. Hernandez, A. Sanchez, M.D. Frutos and P. Parrilla. British Journal of Surgery, September 2009.
Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.
Slide 1 Presented By Jan Buckner at 2014 ASCO Annual Meeting.
D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric Cancer NEJM July vol 359 R2 임규성.
Presented By Michael Overman at 2016 ASCO Annual Meeting
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.
 Exemplary Care  Cutting-edge Research  World-class Education  Title of the paper Your name Critical Care Medicine School of Medicine University of.
A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (Moga) vs Investigator’s Choice (IC) in the Treatment of Patients.
Dr. Marco Matos JOURNAL CLUB GCUH 4/07/14.
Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or.
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Phase III MF07-01 Trial: Impact of Initial Local Resection on Stage.
CCO Independent Conference Highlights
Presented By James Hill at 2016 ASCO Annual Meeting
A cura di Filippo de Marinis
CCO Independent Conference Highlights
Immunoscore Prognostic in Colon Cancer
A Systematic Review and Meta-analysis
PRESENTER NAME Waikato Cardiothoracic Unit Journal Club
Securing the cure in resectable lung cancer
Presented By Michael Lee at 2016 ASCO Annual Meeting
CREATE-X: Adjuvant Capecitabine in HER2-Negative Breast Cancer
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
Presented By Antoni Ribas at 2014 ASCO Annual Meeting
ESPAC-4: Adjuvant Gemcitabine/ Capecitabine Improves 5-Yr Survival vs Gemcitabine Alone in Resected Pancreatic Ductal Carcinoma CCO Independent Conference.
Presented By Marco Colleoni at 2017 ASCO Annual Meeting
Presented By John Bartlett at 2017 ASCO Annual Meeting
Presented By Luca Malorni at 2017 ASCO Annual Meeting
S1207: Phase III randomized, placebo-controlled trial adding 1 year of everolimus to adjuvant endocrine therapy for patients with high-risk, HR+, HER2-
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
New Paradigms for HER2-Positive Early Breast Cancer: Implications and Application.
PCSK9 Inhibitors Post-CVOTs
The Safety and Efficacy of Full vs
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
Adjuvant Radiation is Required for Gastric Cancer
Extraordinary Cases of VTE Prevention in Patients With Cancer
Presented By Praful Ravi at 2016 ASCO Annual Meeting
Efficacy and Safety of Elbasvir/Grazoprevir in Treatment-Naïve patients with Chronic HCV GT 1, GT 4 and GT 6 Infection (C-CORAL): A Phase III Randomized.
ACT II: The Second UK Phase III Anal Cancer Trial
ABSTRACT ABCSG 6a MA17-1 MA.17R NSABP B-33. Extended Adjuvant Therapy With Aromatase Inhibitor Among Postmenopausal Breast Cancer.
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Mohamed K. Kamel, MD, Mohamed Rahouma, MD, Benjamin Lee, MD, Sebron W
Background: Gene Expression
Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting
Presented By Andrew Evens at 2016 ASCO Annual Meeting
• Kaplan-Meier analyses of (A) time-to-recurrence (TTR) for the subgroup of patients with high-risk melanoma who had relapsed (n=82), (B) recurrence-free.
Presentation transcript:

Presented By Shin Fujita at 2016 ASCO Annual Meeting A randomized trial comparing mesorectal excision with or without lateral lymph node dissection for clinical stage II, III lower rectal cancer: Primary endpoint analysis of Japan Clinical Oncology Group Study JCOG0212 Presented By Shin Fujita at 2016 ASCO Annual Meeting

Presented By Shin Fujita at 2016 ASCO Annual Meeting Background Presented By Shin Fujita at 2016 ASCO Annual Meeting

Presented By Shin Fujita at 2016 ASCO Annual Meeting Objective Presented By Shin Fujita at 2016 ASCO Annual Meeting

Presented By Shin Fujita at 2016 ASCO Annual Meeting Study schema Presented By Shin Fujita at 2016 ASCO Annual Meeting

Key eligibility criteria Presented By Shin Fujita at 2016 ASCO Annual Meeting

Presented By Shin Fujita at 2016 ASCO Annual Meeting Endpoints Presented By Shin Fujita at 2016 ASCO Annual Meeting

Summary of operative details and safety Presented By Shin Fujita at 2016 ASCO Annual Meeting

Statistical consideration Presented By Shin Fujita at 2016 ASCO Annual Meeting

Presented By Shin Fujita at 2016 ASCO Annual Meeting CONSORT diagram Presented By Shin Fujita at 2016 ASCO Annual Meeting

Patient Characteristics Presented By Shin Fujita at 2016 ASCO Annual Meeting

Presented By Shin Fujita at 2016 ASCO Annual Meeting Slide 11 Presented By Shin Fujita at 2016 ASCO Annual Meeting

Relapse-free survival [All randomized pts] Presented By Shin Fujita at 2016 ASCO Annual Meeting

Relapse-free survival [All eligible pts] Presented By Shin Fujita at 2016 ASCO Annual Meeting

Overall survival [All randomized pts] Presented By Shin Fujita at 2016 ASCO Annual Meeting

Local-recurrence free survival [All randomized pts] Presented By Shin Fujita at 2016 ASCO Annual Meeting

Classification of local recurrence sites Presented By Shin Fujita at 2016 ASCO Annual Meeting

Local recurrence sites Presented By Shin Fujita at 2016 ASCO Annual Meeting

Subgroup analysis of RFS Presented By Shin Fujita at 2016 ASCO Annual Meeting

Presented By Shin Fujita at 2016 ASCO Annual Meeting Conclusions Presented By Shin Fujita at 2016 ASCO Annual Meeting

Presented By Shin Fujita at 2016 ASCO Annual Meeting Acknowledgement Presented By Shin Fujita at 2016 ASCO Annual Meeting

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.